CSCIF COSCIENS Biopharma Inc. IFRS
Perfumes, Cosmetics & Other Toilet Preparations · OTC · SEC CIK 1113423 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-21.8%
TTM net income YoY32.3%
TTM EPS YoY44.9%
Revenue 3-yr CAGR-19.9%
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-142.5%
Net margin-138.1%
FCF margin-122.4%
EBITDA margin-126.6%
Returns
ROE-121.8%
ROA-36.7%
ROIC (approx.)—
Asset turnover0.27x
Leverage & solvency
Liabilities / assets82.1%
Debt / equity0.00x
Current ratio3.18x
Interest coverage-63.58x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue9.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.50M | $9.59M | $7.14M | $14.57M | $5.26M |
| Cost of revenue | $4.85M | $4.86M | $4.21M | $6.02M | $90,000 |
| Gross profit | $2.65M | $4.73M | $2.94M | $8.56M | $5.17M |
| R&D expense | $2.95M | $8.30M | $2.04M | $1.37M | $6.57M |
| SG&A expense | $10.06M | $10.45M | $5.53M | $2.87M | $7.27M |
| Operating income | -$10.68M | -$18.28M | -$4.63M | $4.32M | -$8.67M |
| Interest expense | $168,000 | $129,000 | $136,000 | $143,000 | — |
| Pretax income | -$10.35M | -$15.22M | -$4.37M | $4.53M | -$8.48M |
| Income tax | $10,000 | $84,000 | -$885,000 | $1.08M | -$109,000 |
| Net income | -$10.36M | -$15.31M | -$3.48M | $3.45M | -$8.37M |
| EBITDA | -$9.49M | -$16.67M | -$3.19M | $5.79M | -$8.53M |
| EPS (basic) | -3.27 | -5.93 | -1.89 | 1.87 | -1.82 |
| EPS (diluted) | -3.27 | -5.93 | -1.89 | 1.86 | -1.82 |
| Weighted avg. shares (diluted) | 3.17M | 2.58M | 1.85M | 1.85M | 4.60M |
| Balance sheet | |||||
| Cash & equivalents | $7.31M | $16.39M | $6.68M | $10.19M | $6.16M |
| Receivables | $1.26M | $2.36M | $290,000 | $732,000 | $1.31M |
| Inventory | $1.31M | $2.69M | $4.01M | $229,000 | — |
| Current assets | $11.50M | $23.98M | $11.27M | $55.49M | $70.82M |
| PP&E, netmay include right-of-use assets (IFRS) | $9.81M | $10.97M | $10.97M | $216,000 | $192,000 |
| Goodwill | — | — | — | — | $8.13M |
| Intangibles | — | — | $7,000 | $9,000 | $625,000 |
| Total assets | $21.43M | $35.07M | $23.75M | $27.84M | $80.10M |
| Current liabilities | $3.61M | $7.22M | $1.31M | $7.04M | $7.77M |
| Total liabilities | $17.59M | $21.91M | $2.71M | $4.02M | $27.12M |
| Shareholders' equity | $3.84M | $13.16M | $21.04M | $23.82M | $21.94M |
| Cash flow statement | |||||
| Operating cash flow | -$8.47M | -$14.57M | -$2.58M | $5.23M | -$8.58M |
| Capital expenditure | $706,000 | $1.16M | $722,000 | $304,000 | $30,000 |
| Free cash flow | -$9.18M | -$15.73M | -$3.30M | $4.92M | -$8.61M |
| Investing cash flow | -$458,000 | $25.08M | -$730,000 | -$304,000 | -$658,000 |
| Financing cash flow | -$407,000 | -$588,000 | -$357,000 | -$267,000 | $51.04M |
| Depreciation & amortization | $1.19M | $1.61M | $1.44M | $1.47M | $144,000 |
| Stock-based compensation | -$12,000 | $464,000 | $192,000 | $69,000 | $311,000 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.